SPOTLIGHT: Cephalon takes careful approach to Nuvigil

The FDA has provided a long-awaited approval for Cephalon's Nuvigil, a new version of its sleep disorder drug Provigil. Final approval had hit a snag with the agency's delays related to describing the drug's side effects on the drug label. Cephalon says it is in no hurry to start marketing the drug. It will await the arrival of more clinical data and won't start selling the therapy this year. Report

Suggested Articles

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.

The appointment gives Sino-American biotech Brii the experience of a man who helped Gilead launch eight drugs in China in quick succession.